Autologous chimeric antigen receptor T cell therapy - Tasly Pharmaceutical Group

Alternative Names: Autologous Tris-CAR-T cell - Tasly Pharmaceutical Group

Latest Information Update: 03 Nov 2022

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Tasly Pharmaceutical Group
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

21 Oct 2022 Preclinical trials in Glioblastoma in China (Intratumoural), before October 2022
13 Oct 2022 Beijing Tiantan Hospital plans a phase I trial for Gliobalstoma (Recurrent) in China in November 2022 (Intratumoral) (NCT05577091)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com